Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel treatments for metabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH.
It is the developer of the first FDA‑approved therapy for adults with moderate to advanced liver fibrosis.
Address: 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428
Phone: (267) 327‑4445
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The Philadelphia Business Journal. The West…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in…
-
Conshohocken’s Madrigal Makes $4B Bet on the Future of Liver Disease Treatment
Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George for The Philadelphia Business Journal.…
-
Madrigal Pharmaceuticals First to Receive FDA Clearance for a NASH Treatment
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver disease that causes inflammation of…
Founding Partners
Advertisement
Affiliate Partners
